Implementation of a Short-term Treatment Protocol in Anemic Patients before Cardiac Surgery

26.08.2025 | Leviner DB, Abraham D, Shiner M, Schwartz N, Lavon O, Sharoni E

Thorac Cardiovasc Surg. 2025 Aug;73(5):360-367. doi: 10.1055/a-2176-2218

Effects of Medical Cannabis Treatment for Autistic Children on Anxiety and Restricted and Repetitive Behaviors and Interests: An Open-Label Study

17.08.2025 | David A, Stolar O, Berkovitch M, Kohn E, Hazan A, Waissengreen D, Gal E

Cannabis Cannabinoid Res. 2025 Aug;10(4):537-548. doi: 10.1089/can.2024.0001

Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial

07.08.2025 | Alabbasi AK, Green MS, Brammli-Greenberg S, Haj MB, Preis M, Schwartz N, Lavon O, Klang S, Cohen S

JCO Oncol Pract. 2025 Aug 1:OP2500158. doi: 10.1200/OP-25-00158

Dexmedetomidine for Less Invasive Surfactant Administration: A Pilot Study

30.06.2025 | Nissimov S, Kohn A, Keidar R, Livne A, Shemer M, Gover A, Hershkovich-Shporen C, Berkovitch M, Morag I

Paediatr Drugs. 2025 Mar

The association of prenatal volatile organic compounds exposure and newborn anthropometrics: A cross-sectional study

22.06.2025 | Michael T, Solt I, Daniel S, Levy A, Hochwald O, Borenstein-Levin L, Hazan A, Berkovitch M, Brik A, Rabin AM, Betser M, Moskovich M, Livne A, Keidar R, Schwartsburd F, Weiner Z, Kohn E

Int J Hyg Environ Health. 2025 Mar

Health disparities in diabetes treatment: The challenge of G6PD deficiency

16.06.2025 | Israel A, Raz I, Green I, Golan-Cohen A, Berkovitch M, Magen E, Vinker S, Merzon E

Diabetes Res Clin Pract. 2025 Jan

Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study

11.06.2025 | Caraco Y, Johnson MG, Chiarappa JA, Maas BM, Stone JA, Rizk ML, Vesnesky M, Strizki JM, Williams-Diaz A, Brown ML, Carmelitano P, Wan H, Pedley A, Chawla A, Wolf DJ, Grobler

JA, Paschke A, De Anda C Clin Trials. 2025 Jun

A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T

06.05.2025 | Caraco Y, Wanounou M, Blotnick S, Friedman L, Cohen A, Hart G, Kerem E

J Cyst Fibros. 2025 Jan;24(1):66-71. doi: 10.1016/j.jcf.2024.10.004